Publication | Closed Access

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

UrologyOncologyMedicinePharmacotherapyCastration-resistant Prostate CancerCancer TreatmentProstatic DiseasePharmacologyOsteoporosisRadium-223 DichloridePhase 3